Eiko LifeSciences Limited (BOM:540204)
India · Delayed Price · Currency is INR 52.11
+0.06 (0.12%)
At close: Feb 13, 2026
Eiko LifeSciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 456.37 | 376.64 | 279.29 | 183.21 | 254.12 | 119.91 |
Other Revenue | -0 | -0 | - | - | - | - |
| 456.37 | 376.64 | 279.29 | 183.21 | 254.12 | 119.91 | |
Revenue Growth (YoY) | 31.17% | 34.85% | 52.44% | -27.90% | 111.93% | 15.18% |
Cost of Revenue | 354.93 | 328.05 | 254.16 | 161.14 | 226.16 | 106.26 |
Gross Profit | 101.45 | 48.59 | 25.14 | 22.07 | 27.96 | 13.65 |
Selling, General & Admin | 9.21 | 7.23 | 2.73 | 3.68 | 2.82 | 1.23 |
Other Operating Expenses | 27.59 | 13.76 | 6.28 | 8.85 | 11.98 | 6.68 |
Operating Expenses | 46.94 | 28.36 | 15.63 | 18.85 | 20.42 | 8.52 |
Operating Income | 54.51 | 20.23 | 9.5 | 3.22 | 7.53 | 5.12 |
Interest Expense | -2.76 | -1.53 | -1.42 | -1.5 | -3.69 | -0.88 |
Interest & Investment Income | 6.93 | 6.93 | 1.82 | 7.27 | 6.42 | 3.58 |
Earnings From Equity Investments | 1.52 | 1.43 | - | - | - | - |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | -0.06 | 0.96 | 0.11 | 0.5 |
Other Non Operating Income (Expenses) | 3.51 | -0.06 | -0 | 0 | -0.95 | - |
EBT Excluding Unusual Items | 63.74 | 27.04 | 9.84 | 9.95 | 9.42 | 8.33 |
Gain (Loss) on Sale of Investments | 0.2 | 0.2 | - | 0.32 | - | - |
Gain (Loss) on Sale of Assets | 0 | 0 | - | - | - | - |
Other Unusual Items | 3.41 | 3.41 | - | - | - | - |
Pretax Income | 67.36 | 30.65 | 9.84 | 10.26 | 9.42 | 8.33 |
Income Tax Expense | 16.65 | 7.46 | 2.33 | 2.58 | 2.36 | 2.18 |
Earnings From Continuing Operations | 50.71 | 23.19 | 7.52 | 7.69 | 7.06 | 6.14 |
Minority Interest in Earnings | -8.3 | -2.13 | - | - | - | - |
Net Income | 42.41 | 21.06 | 7.52 | 7.69 | 7.06 | 6.14 |
Net Income to Common | 42.41 | 21.06 | 7.52 | 7.69 | 7.06 | 6.14 |
Net Income Growth | 208.80% | 180.20% | -2.25% | 8.94% | 14.88% | - |
Shares Outstanding (Basic) | 14 | 13 | 10 | 10 | 8 | 4 |
Shares Outstanding (Diluted) | 14 | 13 | 10 | 10 | 8 | 4 |
Shares Change (YoY) | 7.22% | 26.37% | 5.41% | 25.30% | 104.48% | - |
EPS (Basic) | 3.11 | 1.62 | 0.73 | 0.79 | 0.90 | 1.61 |
EPS (Diluted) | 3.11 | 1.62 | 0.73 | 0.79 | 0.90 | 1.61 |
EPS Growth | 188.01% | 121.73% | -7.26% | -12.72% | -44.03% | - |
Free Cash Flow | - | -73.67 | -74.26 | 39.99 | -78.82 | -8.25 |
Free Cash Flow Per Share | - | -5.65 | -7.20 | 4.09 | -10.09 | -2.16 |
Gross Margin | 22.23% | 12.90% | 9.00% | 12.05% | 11.00% | 11.38% |
Operating Margin | 11.94% | 5.37% | 3.40% | 1.76% | 2.96% | 4.27% |
Profit Margin | 9.29% | 5.59% | 2.69% | 4.20% | 2.78% | 5.12% |
Free Cash Flow Margin | - | -19.56% | -26.59% | 21.83% | -31.02% | -6.88% |
EBITDA | 64.54 | 27.6 | 16.13 | 9.55 | 13.16 | 5.74 |
EBITDA Margin | 14.14% | 7.33% | 5.78% | 5.21% | 5.18% | 4.78% |
D&A For EBITDA | 10.03 | 7.37 | 6.63 | 6.33 | 5.62 | 0.62 |
EBIT | 54.51 | 20.23 | 9.5 | 3.22 | 7.53 | 5.12 |
EBIT Margin | 11.94% | 5.37% | 3.40% | 1.76% | 2.96% | 4.27% |
Effective Tax Rate | 24.71% | 24.35% | 23.64% | 25.09% | 25.09% | 26.23% |
Revenue as Reported | 467.1 | 383.8 | 281.05 | 191.76 | 260.85 | 124.51 |
Advertising Expenses | - | 0.06 | 0.1 | 0.06 | 0.05 | 0.05 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.